CYP2D6 and Plasmodium vivax malaria: The WHO further advocated the personalized dosage of PQ therapy for the eradicative treatment of vivax malaria based on acquired understanding of patients’ CYP2D6 genetic polymorphism and heterogeneity of enzyme activity [14, 15].